Fundz

Grail

Menlo Park, California, United States · Biotechnology, Genetics, Health Care · 1,087 employees

Grail is a healthcare company focused on the early detection of cancer through its innovative liquid biopsy technology. The company aims to transform cancer diagnosis and treatment by providing tools that detect cancer at its earliest stages. Grail's mission is to help save lives through early cancer detection. The firm blends cutting-edge genetic science with next-generation sequencing.

Funding history

  • Funding Round — $388.4M — Nov 2025
  • Series private equity — $325.0M — Oct 2025
  • Funding Round — $388.4M — May 2020
  • Series series d — $390.0M — May 2020
  • Funding Round — $125.0M — Dec 2019

Recent signals

  • Mar 12, 2026: GRAIL, Inc. Appoints Josh Ofman as Chief Executive Officer
  • Nov 13, 2025: SEC 8-K (1.01): On November 13, 2025, GRAIL, Inc. entered into a securities purchase agreement dated October 18, 2025, which resulted in the issuance of a total of 3,925,767 shares of common stock. This includes 1,927,194 shares of common stock and 1,998,573 shares issuable upon the exercise of pre-funded warrants to purchase shares. These transactions involve several selling stockholders as disclosed in the prospectus supplement. The resale of these securities is being filed with the SEC under Rule 424(b), indicating a significant capital market activity undertaken by the company. The strategic implications suggest potential fundraising or liquidity events for the company in the near future.
  • Nov 07, 2025: Raised $388.4M
  • Oct 20, 2025: Raised $325.0M in Series private equity
  • Oct 18, 2025: SEC 8-K (1.01): On October 18, 2025, GRAIL, Inc. entered into a Securities Purchase Agreement with specified purchasers, referred to as the Investors, for a private placement. Under this agreement, GRAIL agreed to sell a total of 4,639,543 shares of its common stock at a par value of $0.001 per share, and some investors were offered prefunded warrants as an alternative to common shares, with an exercise price set at $0.001 per share. This transaction involves raising capital through securities offerings, marking a strategic move intended to strengthen financial positioning. The agreement could lead to future dilution of existing shares if the prefunded warrants are exercised, impacting shareholders' equity.
  • Oct 16, 2025: SEC 8-K (1.01): On October 16, 2025, GRAIL, Inc. entered into a Stock Purchase Agreement with Samsung C&T Corporation, Samsung Electronics Singapore Pte. Ltd., and Samsung Electronics Co., Ltd. The agreement involves the issuance and sale of 1,570,308 shares of common stock at a price of $70.05 per share. This private placement is significant as it represents a substantial capital investment by the Samsung entities in GRAIL, which may enhance GRAIL's operational capabilities and strategic position in the market. The agreement outlines specific terms and conditions that govern the transaction, underscoring its materiality to GRAIL's business operations.
  • Feb 16, 2025: Grail's Stock Surges 30% Following Agreement with Quest
  • May 07, 2020: Raised $388.4M

See plans & pricing → Track Grail’s funding, hiring, and signals — with verified contacts — on Fundz.